ORYL Photonics announces the successful closing of its Series A round. The round was backed by existing shareholders. Their investment commitment has been achieved in record time (two weeks!).

This milestone marks a major step forward for the fast-growing Swiss company, which is pioneering advanced solutions for measuring the solubility and aggregation of drug molecules and biologics in the life science sector. The investment will further accelerate the rollout of its recently launched ORYL F1 platform instrument.